Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Clinical Advances in Immune Thrombocytopenia: Integrating New Therapies
  • CME

Credits Available
Physicians: maximum of 2.5 AMA PRA Category 1 Credits
Released: December 9, 2020 Expiration: December 8, 2021
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Dova Pharmaceuticals, Inc.
David J. Kuter, MD, DPhil
Program Director
Keith R. McCrae, MD
Michael Tarantino, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify treatment-naive patients with ITP who would benefit from intensified therapy to enhance remission rates
  • Plan individualized second-line treatment regimens for ITP that is unresponsive to traditional steroids and splenectomy
  • Select optimal therapy for patients with ITP who have had an insufficient response to corticosteroids, immunoglobulins, splenectomy, and/or a thrombopoietin receptor agonist
  • Evaluate therapeutic strategies to manage thrombocytopenia in special populations of patients, including children, athletes, military, first responders, or those with chronic liver disease or undergoing a planned medical procedure
  • Discuss the available data and ongoing clinical trials investigating novel agents and combination regimens for the treatment of ITP

Information on this Educational Activity

Program Director

David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

David J. Kuter MD, DPhil, has disclosed that he has received funds for research support from Actelion (Syntimmune), Agios, Alnylam, Amgen, Argenx, Bristol-Myers Squibb, Immunovant, Kezar, Principia, Protalex, Rigel, Takeda (Bioverativ) and consulting fees from Actelion (Syntimmune), Agios, Alnylam, Amgen, Argenx, Bristol-Myers Squibb, Caremark, CRICO, Daiichi Sankyo, Dova, Genzyme, Immunovant, Incyte, Kyowa-Kirin, Merck Sharp & Dohme, Momenta, Novartis, Pfizer, Platelet Disorder Support Association, Principia, Protalex, Protalix, Rigel, Sanofi, Genzyme, Shionogi, Shire, Takeda (Bioverativ), UCB, and Zafgen.

Faculty

Keith R. McCrae, MD

Professor of Molecular Medicine
Department of Hematology and Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio, USA

Keith R. McCrae, MD, has disclosed that he has received consulting fees from Dova, Novartis, and Rigel.
Michael Tarantino, MD

Chief Medical Officer
Chief Executive Officer and President

The Bleeding & Clotting Disorders Institute
Professor of Pediatrics and Medicine
University of Illinois College of Medicine at Peoria
Peoria, Illinois

Michael Tarantino, MD, has disclosed that he has received consulting fees from Amgen, Biomarin, Genentech, Grifols, Magellan, Octapharma, Principia, and Takeda and funds for research support from Takeda.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Bing-e Xu, PhD

Scientific Director

Bing-E Xu, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer reports that his spouse has ownership interest in AstraZeneca.

Target Audience

This program is intended for hematologists and other clinicians involved in the management of patients with immune thrombocytopenia.

Goal

The goal of this activity is to improve the knowledge and competence of learners in using new and emerging therapeutic options for patients with ITP.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 09, 2020, through December 08, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Clinical Advances in Immune Thrombocytopenia: Integrating New Therapies
  • CME

Loading...
In this interactive on-demand Webcast from a live CCO Webinar, an expert panel discusses best practices and emerging strategies in managing patients with ITP.
David J. Kuter, MD, DPhil
Program Director
Keith R. McCrae, MD
Michael Tarantino, MD
Physicians: maximum of 2.5 AMA PRA Category 1 Credits
Released: December 9, 2020 Expiration: December 8, 2021

Related Content

Prof. Paul Coppo shares his thoughts on the current management of aTTP using clinical guidelines, biomarkers, and targeted therapies, from Clinical Care Options (CCO)

person default Paul Coppo, MD, PhD Released: October 21, 2021

Expert commentary on current and emerging treatment options for hemophilia A, from Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Released: October 14, 2021

Clinical Care Options (CCO) expert faculty Guy Young, MD, on the evolution of prophylaxis therapy for hemophilia A and adherence challenges with young adult patients

Guy A. Young, MD Released: September 22, 2021

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Dova Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue